Theravance Biopharma Inc Total Assets
Theravance Biopharma Inc total assets. Based on the latest financial reports, Theravance Biopharma Inc (0TB) holds total assets worth €415.46 Million EUR (≈ $485.72 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Theravance Biopharma Inc market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Theravance Biopharma Inc (2014–2024)
Total assets of Theravance Biopharma Inc from 2014 to 2024. This chart illustrates how Theravance Biopharma Inc's total assets have evolved over time, based on quarterly financial data. See Theravance Biopharma Inc (0TB) share price today for real-time trading data and today's change.
Theravance Biopharma Inc - Asset Composition Analysis
Theravance Biopharma Inc Total Assets Breakdown (December 2024)
Theravance Biopharma Inc total assets breakdown as of December 2024. Theravance Biopharma Inc's total assets of €415.46 Million consist of 45.5% current assets and 54.5% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 10.7% |
| Accounts Receivable | €18.44 Million | 5.2% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Theravance Biopharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Theravance Biopharma Inc current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Theravance Biopharma Inc's current assets represent 45.5% of total assets in 2024, a decrease from 81.5% in 2014.
- Cash Position: Cash and equivalents constituted 10.7% of total assets in 2024, down from 26.4% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 5.2% of total assets.
Theravance Biopharma Inc Competitors by Total Assets
Key competitors of Theravance Biopharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Theravance Biopharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.48 | 4.97 | 3.18 |
| Quick Ratio | 9.48 | 4.97 | 3.18 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €317.29 Million | €93.05 Million | €269.77 Million |
Theravance Biopharma Inc - Advanced Valuation Insights
This section examines the relationship between Theravance Biopharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.21 |
| Latest Market Cap to Assets Ratio | 2.34 |
| Asset Growth Rate (YoY) | -7.3% |
| Total Assets | €354.16 Million |
| Market Capitalization | $828.57 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Theravance Biopharma Inc's assets at a significant premium (2.34x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Theravance Biopharma Inc's assets decreased by 7.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Theravance Biopharma Inc (2014–2024)
The table below shows the annual total assets of Theravance Biopharma Inc from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €354.16 Million ≈ $414.05 Million |
-7.29% |
| 2023-12-31 | €382.00 Million ≈ $446.60 Million |
-37.11% |
| 2022-12-31 | €607.40 Million ≈ $710.11 Million |
+62.05% |
| 2021-12-31 | €374.82 Million ≈ $438.20 Million |
-20.09% |
| 2020-12-31 | €469.06 Million ≈ $548.38 Million |
+14.73% |
| 2019-12-31 | €408.83 Million ≈ $477.96 Million |
-27.03% |
| 2018-12-31 | €560.24 Million ≈ $654.97 Million |
+26.92% |
| 2017-12-31 | €441.40 Million ≈ $516.04 Million |
-30.95% |
| 2016-12-31 | €639.25 Million ≈ $747.36 Million |
+113.00% |
| 2015-12-31 | €300.12 Million ≈ $350.87 Million |
-11.15% |
| 2014-12-31 | €337.77 Million ≈ $394.89 Million |
-- |
About Theravance Biopharma Inc
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Its late-stage investigational once-daily norepinephrine reuptake inhibitor, Ampreloxetine is in the development for symptomatic neurogeni… Read more